EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage

Akiyoshi Shimoda, Kazuhiro Murai iD, Hayato Hikita iD, Satoshi Minami iD, Takayuki Miyake, Shinji Kuriki, Emi Sometani, Jihyun Sung, Satoshi Shigeno, Yuichiro Higuchi, Kazuki Maesaka, Kumiko Shirai und 6 weitere

PLOS One · 2026

DOI: 10.1371/journal.pone.0340023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Akiyoshi Shimoda und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Japan. Hauptthemen laut MEDLINE: Auranofin, Hepatitis B Surface Antigens, Antiviral Agents, Hepatitis B virus. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Gilead Sciences, Inc., GSK plc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aim Hepatitis B surface antigen (HBsAg) is associated with hepatocellular carcinoma risk and immune exhaustion and contributes to hepatitis B virus (HBV) persistence. Current anti-HBV treatments have a limited ability to reduce HBsAg levels. This study aimed to identify FDA-approved drugs capable of reducing HBsAg levels and explore the underlying mechanisms.

Methods

A total of 1134 FDA-approved compounds were screened at 9.9 μM for 7 days using HepG2.2.15.7 cells, which contain an integrated HBV genome. HBsAg in the supernatant and cell viability were assessed. Compounds whose viability was reduced by >1 SD were excluded. Compounds whose HBsAg concentration decreased by >1.5 SD were selected and validated at 0.5 and 5 μM. We evaluated the HBsAg-reducing effect of the final candidate compounds using HBV-infected primary human hepatocytes (HepaSH cells) derived from chimeric TK-NOG mice and investigated the underlying mechanism responsible for the reduction in HBsAg.

Results

After 126 cytotoxic compounds were excluded, the HBsAg levels of the 6 candidates decreased by >1.5 SD. Ethacridine and auranofin significantly reduced the level of HBsAg at both 5 and 0.5 μM. In HepaSH cells, only auranofin decreased the level of HBsAg. Auranofin did not affect the HBe antigen, HBV-DNA, or pregenomic RNA, nor did it reduce the level of intracellular HBsAg, as determined by Western blotting. Transmission electron microscopy revealed more vesicles in auranofin-treated HepaSH cells than in control cells. Immunofluorescence analysis of HepaSH cells treated with auranofin revealed increased Galectin-3 expression and colocalization of HBsAg with Galectin-3, which was consistent with lysosomal damage, compared with those of the untreated controls.

Conclusion

Auranofin, an FDA-approved antirheumatic agent, reduces HBsAg secretion via lysosomal damage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AuranofinHepatitis B Surface AntigensAntiviral AgentsHepatitis B virusHepatitis BDrug ApprovalUnited States Food and Drug AdministrationUnited StatesLysosomesAntirheumatic AgentsDrug Evaluation, PreclinicalHep G2 CellsMice, TransgenicHumansAnimalsMice

Substanzen

AuranofinHepatitis B Surface AntigensAntirheumatic AgentsAntiviral Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Japan.
  • Department of Genetics, The University of Osaka Graduate School of Medicine, Suita, Japan.
  • Liver Engineering Laboratory, Department of Research for Humanized Model, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.
  • Immunology Laboratory, Department of Medical Innovation, Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan.

ORCID-Profile: Kazuhiro Murai, Hayato Hikita, Satoshi Minami, Yuki Tahata

Förderung

  • Japan Agency for Medical Research and Development
  • Gilead Sciences, Inc.
  • GSK plc.
  • Bristol Myers Squibb
  • Basis for Supporting Innovative Drug Discovery and Life Science Research

Zitieren

APA

Shimoda, A., Murai, K., Hikita, H., Minami, S., Miyake, T., Kuriki, S., Sometani, E., Sung, J., Shigeno, S., Higuchi, Y., Maesaka, K., Shirai, K., Tahata, Y., Saito, Y., Kodama, T., Takahashi, T., Suemizu, H., & Takehara, T. (2026). Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage. PLOS One. https://doi.org/10.1371/journal.pone.0340023

Vancouver

Shimoda A, Murai K, Hikita H, Minami S, Miyake T, Kuriki S, et al. Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage. PLOS One. 2026. doi:10.1371/journal.pone.0340023

BibTeX
@article{Shimoda2026,
  author = {Shimoda, Akiyoshi and Murai, Kazuhiro and Hikita, Hayato and Minami, Satoshi and Miyake, Takayuki and Kuriki, Shinji and Sometani, Emi and Sung, Jihyun and Shigeno, Satoshi and Higuchi, Yuichiro and Maesaka, Kazuki and Shirai, Kumiko and Tahata, Yuki and Saito, Yoshinobu and Kodama, Takahiro and Takahashi, Takeshi and Suemizu, Hiroshi and Takehara, Tetsuo},
  title = {Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0340023}
}
Kostenlos starten →